Unleashing endogenous TNF-alpha as a cancer immunotherapeutic (original) (raw)
Systemic use of tumor necrosis factor alpha as an anticancer agent
Shibin Zhou
Oncotarget, 2011
View PDFchevron_right
Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma
Sandra T van Tiel
Annals of Surgical Oncology, 2002
View PDFchevron_right
TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
J. de Wilt
British journal of cancer, 2000
View PDFchevron_right
TNF α augments intratumoural concentrations of doxorubicin in TNF α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
Sandra T van Tiel
British Journal of Cancer, 2000
View PDFchevron_right
Isolated single-lung perfusion with TNF-α in a rat sarcoma lung metastases model
Bruce Ng
The Annals of Thoracic Surgery, 1994
View PDFchevron_right
In vivo isolated kidney perfusion with tumour necrosis factor alpha (TNF-alpha) in tumour-bearing rats
Alexander Van der Veen
British journal of cancer, 1999
View PDFchevron_right
In vivo isolated kidney perfusion with tumour necrosis factor α (TNF-α) in tumour-bearing rats
Peet Nooijen
British Journal of Cancer, 1999
View PDFchevron_right
Tumor necrosis factor: clinical use and mechanisms of action
Olivier Dormond, Delphine Oguey
Drug Resistance Updates, 2000
View PDFchevron_right
Regional Administration of Recombinant Tumour Necrosis Factor-?? in Cancer, with Special Reference to Melanoma
Alexander Eggermont
BioDrugs, 1998
View PDFchevron_right
Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin
Roberto Accolla
Clinical Cancer Research, 2006
View PDFchevron_right
Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion
Joost Rens
International Journal of Cancer, 2006
View PDFchevron_right
In vivo targets of recombinant human tumour necrosis factor-α: blood flow, oxygen consumption and growth of isotransplanted rat tumours
Peter Vaupel
British Journal of Cancer, 1989
View PDFchevron_right
Technology Insight: utility of TNF-α-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities
J. de Wilt
Nature Clinical Practice Oncology, 2006
View PDFchevron_right
IncreasedTIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-? to patients with soft tissue limb sarcoma
Maurizio Provenzano
International Journal of Cancer, 2003
View PDFchevron_right
Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat
Peet Nooijen
British Journal of Surgery, 1996
View PDFchevron_right
Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF- be better?
Nathalie Lassau, Axel Le Cesne
Annals of Oncology, 2005
View PDFchevron_right
Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy
Florencia Mercogliano
Cancers
View PDFchevron_right
Selective targeted delivery of TNFα to tumor blood vessels
Annalisa Siri
Blood, 2003
View PDFchevron_right
Targeted Delivery of Tumor Necrosis Factor- to Tumor Vessels Induces a Therapeutic T Cell-Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin
Roberto Accolla
Clinical Cancer Research, 2006
View PDFchevron_right
Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity
Sandra T van Tiel
British Journal of Cancer, 2002
View PDFchevron_right
Targeting TNF-α to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy
Angelo Corti
The Journal of Immunology, 2012
View PDFchevron_right
Compromised anti-tumor responses in tumor necrosis factor-α knockout mice
Ioannis Voutsas
European Journal of Immunology, 2000
View PDFchevron_right
Tumor-targeted gene delivery of tumor necrosis factor-α induces tumor necrosis and tumor regression without systemic toxicity
Ralf Kircheis
Cancer Gene Therapy, 2002
View PDFchevron_right
Antitumor effect of recombinant tumor necrosis factor-? against murine sarcomas at visceral sites: tumor size influences the response to therapy
Rene Lafreniere
Cancer Immunology Immunotherapy, 1988
View PDFchevron_right
Injection of recombinant tumor necrosis factor directly into liver metastases: an experimental and clinical approach
J. Jeekel
Clinical & Experimental Metastasis, 1992
View PDFchevron_right
In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial-monocyte activating polypeptide II (EMAPII)
Peter Wu
Cancer research, 1999
View PDFchevron_right
Selective targeted delivery of TNF to tumor blood vessels
Annalisa Siri
Blood, 2003
View PDFchevron_right
The palliative value of tumor necrosis factor α-based isolated limb perfusion in patients with metastatic sarcoma and melanoma
Alexander Eggermont
Cancer, 2006
View PDFchevron_right
An Attenuated Targeted-TNF Localizes to Tumors In Vivo and Regains Activity at the Site of Disease
Samuele Cazzamalli
International Journal of Molecular Sciences
View PDFchevron_right